SPX4,280.15+72.88 1.73%
DIA337.83+4.12 1.23%
IXIC13,047.19+267.27 2.09%

Better Therapeutics Completes Pivotal Trial Of BT-001 For Type 2 Diabetes And Announces Positive Secondary Endpoint Results Following The Earlier Announcement Of Positive Primary Endpoint Results

Data demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment On track to submit a de novo classification request with FDA for BT-001 in third quarter of 2022 Company to

Benzinga · 07/28/2022 07:39

Data demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment

On track to submit a de novo classification request with FDA for BT-001 in third quarter of 2022

Company to host conference call and webcast today at 8:30 a.m. ET